Ascendis Pharma A/S (ASND) Set to Announce Quarterly Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND) is scheduled to be announcing its earnings results on Thursday, April 25th.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.15) by $0.49. The business had revenue of $148.62 million for the quarter, compared to the consensus estimate of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $144.83 on Wednesday. The stock has a 50 day moving average price of $149.15 and a 200-day moving average price of $125.48. Ascendis Pharma A/S has a one year low of $66.03 and a one year high of $161.00. The stock has a market cap of $8.43 billion, a price-to-earnings ratio of -15.66 and a beta of 0.50.

Analyst Upgrades and Downgrades

ASND has been the subject of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $173.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, April 18th. Morgan Stanley reiterated an “equal weight” rating and set a $116.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday. Wells Fargo & Company lifted their price objective on Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Wedbush boosted their target price on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Finally, Citigroup upped their price objective on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a “buy” rating in a research report on Thursday, February 8th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $173.25.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.